{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:14:53Z","timestamp":1769055293115,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010982","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000}}],"reference-count":247,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010982.pub2","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T14:51:32Z","timestamp":1471877492000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation"],"prefix":"10.1002","volume":"2016","author":[{"given":"Michael","family":"Desborough","sequence":"first","affiliation":[{"name":"NHS Blood and Transplant; Haematology\/Transfusion Medicine; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Haematology\/Transfusion Medicine; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; John Radcliffe Hospital Oxford UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University of Oxford; Oxford Clinical Trials Research Unit; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Windmill Road Oxford Oxfordshire UK OX3 7LD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J","family":"Stanworth","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust and University of Oxford; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital, Headley Way Headington Oxford UK OX3 9BQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Murphy","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust and University of Oxford; NHS Blood and Transplant; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V94.11.3694","article-title":"A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia","volume":"94","author":"Archimbaud","year":"1999","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V94.11.3694","article-title":"A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia","volume":"94","author":"Archimbaud","year":"1999","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-003-0737-7","article-title":"Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study","volume":"82","author":"Geissler","year":"2003","journal-title":"Annals of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-003-0737-7","article-title":"Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study","volume":"82","author":"Geissler","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0005|cit5","unstructured":"A compare study on human recombinant thrombopoietin (TPIAO) promote platelet recovery in haploidentical hematopoietic stem cell transplantation recipients Chinese clinical trial registry number: ChiCTR-TRC-11001774"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00277-014-2158-1","article-title":"Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial","volume":"94","author":"Han","year":"2015","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1537-2995.1974.tb04558.x","article-title":"The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study","volume":"14","author":"Higby","year":"1974","journal-title":"Transfusion"},{"issue":"5","key":"10.1002\/14651858.CD010982.pub2-BIB0008|cit8","first-page":"231","article-title":"Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Miao","year":"2012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdm341","article-title":"Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"18","author":"Moskowitz","year":"2007","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010982.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdm341","article-title":"Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"18","author":"Moskowitz","year":"2007","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010982.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"American Society of Hematology Meeting highlights from 45th annual meeting of the American Society of Hematology Clinical Lymphoma 2003 141 8","DOI":"10.2165\/00128413-200414240-00020"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"2","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0014|cit14","first-page":"437","article-title":"A multi-centre clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"26","author":"Bai","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae"},{"issue":"5","key":"10.1002\/14651858.CD010982.pub2-BIB0015|cit15","first-page":"397","article-title":"The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia","volume":"84","author":"Bai","year":"2004","journal-title":"Zhonghua yi xue za zhi"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0b013e328356e909","article-title":"Thrombopoietin-receptor agonists","volume":"19","author":"Basciano","year":"2012","journal-title":"Current Opinion in Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(96)04471-6","article-title":"Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer","volume":"348","author":"Basser","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0018|cit18","first-page":"3118","article-title":"Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer","volume":"89","author":"Basser","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2000.18.15.2852","article-title":"Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer","volume":"18","author":"Basser","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1381612023395989","article-title":"The impact of thrombopoietin on clinical practice","volume":"8","author":"Basser","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0091270010372106","article-title":"Effect of hepatic or renal impairment on eltrombopag pharmacokinetics","volume":"51","author":"Bauman","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/00912700222011553","article-title":"Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy","volume":"42","author":"Bernstein","year":"2002","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1246-7820(01)00127-6","article-title":"Novel platelet products, substitutes and alternatives","volume":"8","author":"Blajchman","year":"2001","journal-title":"Transfusion Clinique et Biologique"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1046\/j.1538-7836.2003.00332.x","article-title":"Substitutes and alternatives to platelet transfusions in thrombocytopenic patients","volume":"1","author":"Blajchman","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0781.2010.00538.x","article-title":"Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial","volume":"26","author":"Bowen","year":"2010","journal-title":"Photodermatology, Photoimmunology & Photomedicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V104.11.1135.1135","article-title":"Activated recombinant factor VII (rFVIIa\/NovoSeven\u00ae) in the treatment of bleeding complications following hematopoietic stem cell transplantation (HSCT)","volume":"104","author":"Brenner","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/jco.2006.24.18_suppl.8602","article-title":"Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects","volume":"24","author":"Bussel","year":"2006","journal-title":"Journal of Clinical Oncology: Asco Annual Meeting Proceedings"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"Abstract 1299","DOI":"10.1182\/blood.V110.11.1299.1299","article-title":"Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0029|cit29","first-page":"584","article-title":"Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies","volume":"82","author":"Castaman","year":"1997","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.medcli.2015.03.014","article-title":"Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: an updated systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Catal\u00e1-L\u00f3pez","year":"2015","journal-title":"Medicina Clinica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"A364","DOI":"10.1016\/j.jval.2011.08.727","article-title":"Thromboembolisms with thrombopoietin receptor agonists: systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Corrales-Alvarez","year":"2011","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"Abstract 4657","DOI":"10.1182\/blood.V124.21.4657.4657","article-title":"4657 final analysis of a Phase II study of intrapatient dose-escalation of eltrombopag in patients receiving azacitidine for myelodysplasia\/AML","volume":"124","author":"Dickinson","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0033|cit33","unstructured":"New drugs - drug news P&T: Journal for Formulary Management 2005 624 69"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0034|cit34","unstructured":"New drugs\/drug news P&T: Journal for Formulary Management 2006 638"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1213\/01.ANE.0000118105.85933.8A","article-title":"Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?","volume":"99","author":"Dunser","year":"2004","journal-title":"Anesthesia & Analgesia"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bbmt.2014.03.015","article-title":"Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation","volume":"20","author":"Elinoff","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0037|cit37","unstructured":"EudraCT number 2010-022890-33 Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes EudraCT number 2010-022890-33"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0038|cit38","unstructured":"EudraCT number 2014-000174-19 Efficacy and safety of eltrombopag in patients with acquired moderate aplastic anemia (EMAA) who are treated with ciclosporin A EudraCT number 2014-000174-19"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bmt.1705670","article-title":"The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review","volume":"39","author":"Franchini","year":"2007","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"Abstract 3576","DOI":"10.1182\/blood.V120.21.3576.3576","article-title":"A phase I clinical trial using eltrombopag in patients with acute myelogenous leukemia","volume":"120","author":"Frey","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1537-2995.1991.31491213301.x","article-title":"Lack of efficacy of tranexamic acid in thrombocytopenic bleeding","volume":"31","author":"Fricke","year":"1991","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0042|cit42","first-page":"202a","article-title":"Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia","volume":"62","author":"Gallardo","year":"1983","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"Abstract 117","DOI":"10.1182\/blood.V118.21.117.117","article-title":"Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study","volume":"118","author":"Giagounidis","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.13037","article-title":"Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes","volume":"167","author":"Sekeres","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0047|cit47","first-page":"7a","article-title":"The impact of therapy with recombinant granulocyte colony stimulated factor (GCSF) on the health care costs associated with cancer chemotherapy","volume":"78","author":"Glaspy","year":"1991","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428194.2012.713477","article-title":"A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine","volume":"54","author":"Greenberg","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0049|cit49","first-page":"349","article-title":"Agents to control bleeding show promise","volume":"297","author":"Hampton","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1995.tb08924.x","article-title":"The use of anti-D to improve post-transfusion platelet response: a randomized trial","volume":"89","author":"Heddle","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0051|cit51","first-page":"Abstract WP-O01","article-title":"Efficiency and safety of thrombopoietin in moderate aplastic anemia-EMAA trial","volume":"49","author":"Ho\u0308chsmann","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1182\/blood.V122.21.4186.4186","article-title":"A phase II trial of eltrombopag for patients with chronic lymphocytic leukemia (CLL) and thrombocytopenia","volume":"122","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0053|cit53","unstructured":"NCT01168921 Phase II eltrombopag in chronic lymphocytic leukemia (CLL) clinicaltrials.gov\/ct2\/show\/NCT01168921"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2008.01063.x","article-title":"Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials","volume":"95","author":"Johansson","year":"2008","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"Abstract 1885","DOI":"10.1182\/blood.V116.21.1885.1885","article-title":"Update from an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients (pts) with myelodysplastic syndromes (MDS)","volume":"116","author":"Fenaux","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"Abstract 2772","DOI":"10.1182\/blood.V118.21.2772.2772","article-title":"Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS)","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"Abstract 2772","DOI":"10.1016\/S0145-2126(11)70217-X","article-title":"Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS)","volume":"35","author":"Fenaux","year":"2011","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0058|cit58","first-page":"Abstract 97","article-title":"Characteristics of romiplostim-treated MDS patients with hematologic improvement in platelets (HI-P)","volume":"S1","author":"Fenaux","year":"2015","journal-title":"Leukaemia Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"81a","DOI":"10.1182\/blood.V110.11.250.250","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood.V122.21.1553.1553","article-title":"Treatment with romiplostim, a thrombopoietin-receptor agonist, in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: Updated follow-up results for acute myeloid leukemia and survival from a randomized, double-blind, placebo-controlled study","volume":"122","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"Abstract 421","DOI":"10.1182\/blood.V120.21.421.421","article-title":"Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (PTS) with low or intermediate-1 (INT-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"Abstract 3276","DOI":"10.1182\/blood.V124.21.3276.3276","article-title":"Treatment with romiplostim, a thrombopoietin-receptor agonist, in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): updated follow-up results for acute myeloid leukemia (AML) and survival from a randomized, double-blind, placebo (PBO)-controlled study","volume":"124","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0064|cit64","unstructured":"NCT00303472 Determination of safe dose of romiplostim (AMG 531) in patients with myelodysplastic syndromes (MDS) clinicaltrials.gov\/ct2\/show\/NCT00303472"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1038\/leu.2014.253","article-title":"Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial","volume":"28","author":"Platzbecker","year":"2014","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-03-274753","article-title":"Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0068|cit68","first-page":"Abstract 348","article-title":"Evaluation of laboratory desmopressin testing and clinical effects in patients with hereditary and acquired thrombocytopathies: results of a retrospective multicenter study","volume":"11","author":"Knoefler","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/ALN.0b013e318194b21e","article-title":"Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding","volume":"110","author":"Korte","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0070|cit70","first-page":"155a","article-title":"Recombinant factor VIIa (rFVIIa) reduces the bleeding time in patients with thrombocytopenia","volume":"82","author":"Kristensen","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0071|cit71","first-page":"1127","article-title":"Effect of testosterone propionate and 1-methyl-1-androstenolone on blood coagulation factors, bromsulphalein retention and serum enzymes as parameters of liver function","volume":"44","author":"Kruskemper","year":"1966","journal-title":"Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CCO.0b013e32831369b2","article-title":"The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"20","author":"Levy","year":"2008","journal-title":"Current Opinion in Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0073|cit73","first-page":"1064","article-title":"Prophylactic recombinant human thrombopoietin treatment alleviates chemotherapy-induced thrombocytopenia in tumor patients","volume":"32","author":"Li","year":"2012","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbmt.2013.10.002","article-title":"A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation","volume":"19","author":"Liesveld","year":"2013","journal-title":"Biology of Blood & Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"Abstract 3295","DOI":"10.1182\/blood.V118.21.3295.3295","article-title":"Phase I study of eltrombopag for promoting thrombopoiesis in patients undergoing stem cell transplantation after total body irradiation","volume":"118","author":"Liesveld","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"Abstract 219","DOI":"10.1182\/blood.V120.21.219.219","article-title":"Phase I study of eltrombopag for promoting thrombopoiesis in patients undergoing stem cell transplantation after total body irradiation","volume":"120","author":"Liesveld","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0077|cit77","first-page":"649","article-title":"Trial of a new hemostatic: dicynone","volume":"22","author":"Louis","year":"1967","journal-title":"Revue M\u00e9dicale de Li\u00e8ge"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0078|cit78","first-page":"319","article-title":"Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients","volume":"117","author":"Malyszko","year":"1990","journal-title":"Folia Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V67.4.1148.1148","article-title":"Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time","volume":"67","author":"Mannucci","year":"1986","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1705724","article-title":"Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels","volume":"40","author":"Matsumoto","year":"2007","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0081|cit81","first-page":"105","article-title":"Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-week open-label part of an ongoing study","volume":"82","author":"Mittelman","year":"2012","journal-title":"Archivos de Cardiologia de Mexico"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0082|cit82","first-page":"149","article-title":"Exogenous endothelial cells as accelerators of hematopoietic reconstitution","volume":"26","author":"Mizer","year":"1998","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"Abstract 4869","DOI":"10.1182\/blood.V108.11.4869.4869","article-title":"Erythropoietin (EPO) and granulocyte colony stimulating factor (GCS-F) based therapy in patients with low risk MDS: a single centre experience from India","volume":"108","author":"Nair","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation","volume":"6","author":"Nash","year":"2000","journal-title":"Biology of Blood & Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1359-6349(09)71939-1","article-title":"Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"7","author":"Natale","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0086|cit86","unstructured":"NCT00102726 SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adult cancer patients receiving chemotherapy clinicaltrials.gov\/ct2\/show\/NCT00102726"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0087|cit87","unstructured":"NCT00358540 Dose finding study of oral eltrombopag in patients with sarcoma receiving adriamycin and ifosfamide clinicaltrials.gov\/ct2\/show\/NCT00358540"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0088|cit88","unstructured":"NCT00413283 Dose\/schedule finding trial of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC) clinicaltrials.gov\/ct2\/show\/NCT00413283"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0089|cit89","unstructured":"NCT00472290 An open label extension study evaluating the safety of long term dosing of romiplostim in thrombocytopenic subjects with myelodysplastic syndromes (MDS) clinicaltrials.gov\/ct2\/show\/NCT00472290"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0090|cit90","unstructured":"NCT00614523 Romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk myelodysplastic syndrome (MDS) clinicaltrials.gov\/ct2\/show\/NCT00614523"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0091|cit91","unstructured":"NCT00688272 Study in healthy subjects to evaluate the photo-irritant potential of eltrombopag clinicaltrials.gov\/ct2\/show\/NCT00688272"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0092|cit92","unstructured":"NCT00903422 Eltrombopag treatment of thrombocytopenia in subjects with advanced myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia after MDS (sAML\/MDS) clinicaltrials.gov\/ct2\/show\/NCT00903422"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0093|cit93","unstructured":"NCT00922883 A pilot study of a thrombopoietin-receptor agonist (TPO-R agonist), eltrombopag, in aplastic anemia patients with immunosuppressive-therapy refractory thrombocytopenia clinicaltrials.gov\/ct2\/show\/NCT00922883"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0094|cit94","unstructured":"NCT01072162 Relative bioavailibility for pediatric powder for suspension (PfOS) formulation and food effect clinicaltrials.gov\/ct2\/show\/NCT01072162"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0095|cit95","unstructured":"NCT01147809 Safety and efficacy study for solid tumor patients treated with eltrombopag clinicaltrials.gov\/ct2\/show\/NCT01147809"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0096|cit96","unstructured":"NCT01194167 Study of eltrombopag in platelet refractory thrombocytopenia clinicaltrials.gov\/ct2\/show\/NCT01194167"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0097|cit97","unstructured":"NCT01328587 A pilot study of a thrombopoietin-receptor agonist (TPO-R agonist), eltrombopag, in moderate aplastic anemia patients clinicaltrials.gov\/ct2\/show\/NCT01328587"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0098|cit98","unstructured":"NCT01500538 A pilot study of oral vorinostat plus oral eltrombopag support in patients with lymphoma (VEIL) clinicaltrials.gov\/ct2\/show\/NCT01500538"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0099|cit99","unstructured":"NCT01516619 Secondary prophylaxis in non-Hodgkin lymphoma (NHL) and chemotherapy-induced thrombocytopenia (ProRom) clinicaltrials.gov\/ct2\/show\/NCT01516619"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0100|cit100","unstructured":"NCT01550185 Eltrombopag olamine in treating patients with relapsed\/refractory acute myeloid leukemia clinicaltrials.gov\/ct2\/show\/NCT01550185"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0101|cit101","unstructured":"NCT01757145 Eltrombopag for enhancing platelet engraftment in adult patients undergoing cord blood transplantation clinicaltrials.gov\/ct2\/show\/NCT01757145"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0102|cit102","unstructured":"NCT01791101 Eltrombopag in patients with delayed post transplant thrombocytopenia (ITP0511) clinicaltrials.gov\/ct2\/show\/NCT01791101"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0103|cit103","unstructured":"NCT01893372 Eltrombopag with or without hypomethylating agent after hypomethylating agent failure for patients with myelodysplastic syndrome (MDS) clinicaltrials.gov\/ct2\/show\/NCT01893372"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0104|cit104","unstructured":"NCT01957176 A rollover study to provide continued treatment with eltrombopag clinicaltrials.gov\/ct2\/show\/NCT01957176"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0105|cit105","unstructured":"NCT01980030 Using ROMIPLOSTINE for persistent thrombocytopenia with transfusion-dependent patients who received allogeneic hematopoietic stem cell (AGRAH003) clinicaltrials.gov\/ct2\/show\/NCT01980030"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0106|cit106","unstructured":"NCT02046291 Safety of romiplostim (Nplate\u00ae) following UCBT clinicaltrials.gov\/ct2\/show\/NCT02046291"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0107|cit107","unstructured":"NCT02052882 Study of romiplostim versus observation for chemotherapy induced thrombocytopenia clinicaltrials.gov\/ct2\/show\/NCT02052882"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0108|cit108","unstructured":"NCT02093325 A randomized, double blind, placebo-controlled study to assess the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with gynecologic cancer clinicaltrials.gov\/ct2\/show\/NCT02093325"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0109|cit109","unstructured":"NCT02094417 A phase 2 study to evaluate the efficacy and safety of AMG531 in aplastic anemia clinicaltrials.gov\/ct2\/show\/NCT02094417"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0110|cit110","unstructured":"NCT02323178 A study of eltrombopag in patients with CMML and thrombocytopenia clinicaltrials.gov\/ct2\/show\/NCT02323178"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0111|cit111","unstructured":"NCT02446145 A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients (DELTA) clinicaltrials.gov\/ct2\/show\/NCT02446145"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0112|cit112","first-page":"20","article-title":"Serious adverse drug reactions (sADRS) associated with hematopoietic growth factors: a systematic review from the southern network on adverse reactions (SONAR) program","volume":"17","author":"Norris","year":"2011","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0113|cit113","first-page":"Abstract 1138","article-title":"Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and int-1 risk MDS: preliminary results of a prospective, randomized, single-blind placebo-controlled trial","volume":"S1","author":"Oliva","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0114|cit114","first-page":"Abstract S1110","article-title":"Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: results of a prospective, randomized, trial","volume":"98","author":"Oliva","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"Abstract 923","DOI":"10.1182\/blood.V120.21.923.923","article-title":"Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQOL-MDS)","volume":"120","author":"Oliva","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"Abstract 54","DOI":"10.1182\/blood.V118.21.54.54","article-title":"Eltrombopag can stimulate trilineage hematopoiesis with transfusion independence in patients with refractory severe aplastic anemia: results from a phase II trial","volume":"118","author":"Olnes","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7150\/ijms.5.87","article-title":"TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders","volume":"5","author":"Palmblad","year":"2008","journal-title":"International Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.drudis.2008.06.002","article-title":"Emerging treatments for thrombocytopenia: increasing platelet production","volume":"13","author":"Peeters","year":"2008","journal-title":"Drug Discovery Today"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1538-7836.2005.01523.x","article-title":"Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation","volume":"3","author":"Pihusch","year":"2005","journal-title":"Journal of Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0121|cit121","first-page":"Abstract S1108","article-title":"Placebo-controlled, randomized, phase I\/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myeloid leukemia","volume":"98","author":"Platzbecker","year":"2013","journal-title":"Haematologica"},{"issue":"S1","key":"10.1002\/14651858.CD010982.pub2-BIB0122|cit122","first-page":"Abstract P241","article-title":"Randomized, placebo (PBO)-controlled, phase I\/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS)","volume":"100","author":"Platzbecker","year":"2014","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","article-title":"Safety and tolerability of eltrombopag versus placebo for the treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial","volume":"2","author":"Platzbecker","year":"2015","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bjh.13088","article-title":"Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials","volume":"167","author":"Prica","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"Abstract 2806","DOI":"10.1182\/blood.V122.21.2806.2806","article-title":"Thrombopoietin (TPO)-receptor agonists in myelodysplastic syndromes (MDS): a systematic review and meta-analysis","volume":"122","author":"Prica","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1055\/s-2008-1070225","article-title":"Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study","volume":"107","author":"Rasche","year":"1982","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0127|cit127","first-page":"179","article-title":"Substitution with blood coagulation factor XIII concentrates in patients with acute leukemia","volume":"15","author":"Rasche","year":"1986","journal-title":"Beitrage Zu Infusionstherapie und Klinische Ernahrung"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0128|cit128","first-page":"Abstract WPO-00","article-title":"The RACE study: a SAAWP prospective randomized multicenter study comparing horse antithymocyte globulin (HATG) + cyclosporine A (CSA) with or without eltrombopag as front-line therapy for severe aplastic anaemia patients","volume":"49","author":"Risitano","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0301-472X(02)00878-0","article-title":"The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation","volume":"30","author":"Schuster","year":"2002","journal-title":"Experimental Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.25545","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000189519","article-title":"Low-dose intranasal desmopressin (DDAVP) for uremic bleeding","volume":"75","author":"Seza","year":"1997","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0132|cit132","first-page":"547a","article-title":"A controlled trial of tranexamic acid (TA) treatment for reduction of bleeding during acute myeloid leukemia (AML) induction and consolidation","volume":"82","author":"Shpilberg","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V93.9.2798","article-title":"Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy","volume":"93","author":"Somlo","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/157488607780598278","article-title":"Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety","volume":"2","author":"Squizzato","year":"2007","journal-title":"Current Drug Safety"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.12383","article-title":"A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine","volume":"93","author":"Svensson","year":"2014","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00277-001-0391-x","article-title":"Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome","volume":"81","author":"Takami","year":"2002","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM\/EPO MDS Study Group","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"issue":"S1","key":"10.1002\/14651858.CD010982.pub2-BIB0138|cit138","first-page":"Abstract 56","article-title":"Eltrombopag for low to intermediate-2 risk myelodysplastic syndrome","volume":"39","author":"Townsley","year":"2015","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0037-1963(00)90050-7","article-title":"Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia","volume":"37","author":"Vadhan-Raj","year":"2000","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0140|cit140","first-page":"527","article-title":"Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial","volume":"17","author":"Vannucchi","year":"1996","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000225909","article-title":"Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis","volume":"121","author":"Wang","year":"2009","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-8722-5-71","article-title":"A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide","volume":"5","author":"Wang","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-013-1819-9","article-title":"Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis","volume":"92","author":"Wang","year":"2013","journal-title":"Annals of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733.pub2","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders","author":"Wardrop","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"Abstract C026","DOI":"10.1016\/S0145-2126(09)70064-5","article-title":"The non-peptide thrombopoietin receptor agonist eltrombopag (SB-497115, Promacta\/Revolade) does not stimulate malignant growth of bone marrow cells from patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"33","author":"Will","year":"2009","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0146|cit146","first-page":"Abstract 0185","article-title":"Effect of the non-peptide Thrombopoietin receptor agonist eltrombopag (promacta\/revoladetm) on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"94","author":"Will","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","article-title":"Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies","volume":"31","author":"Williams","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Medicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"Abstract 9117","DOI":"10.1200\/jco.2012.30.15_suppl.9117","article-title":"Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): a phase I study","volume":"30","author":"Winer","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clinthera.2012.01.011","article-title":"A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS","volume":"34","author":"Wire","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.bmt.1702772","article-title":"Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study","volume":"27","author":"Wolff","year":"2001","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"Abstract TPS184","DOI":"10.1200\/jco.2010.28.15_suppl.tps184","article-title":"Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: a phase I\/II study","volume":"28","author":"Wroblewski","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jcrc.2013.11.023","article-title":"Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study","volume":"29","author":"Wu","year":"2014","journal-title":"Journal of Critical Care"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0154|cit154","first-page":"716","article-title":"Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients","volume":"30","author":"Xu","year":"2008","journal-title":"Chung-Hua Chung Liu Tsa Chih"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0155|cit155","unstructured":"EudraCT number 2015-000929-37 EPAG 2015: a phase II randomized placebo-controlled study to assess the impact on outcome of eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy EudraCT number 2015-000929-37"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0156|cit156","unstructured":"NCT01397149 Eltrombopag in thrombocytopenic chronic lymphocytic leukemia (CLL) patients (CLL2S study of GCLLSG) clinicaltrials.gov\/ct2\/show\/NCT01397149"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0157|cit157","unstructured":"NCT01656252 Trial of eltrombopag during consolidation therapy in adults with AML in complete remission clinicaltrials.gov\/ct2\/show\/NCT01656252"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0158|cit158","unstructured":"NCT01890746 A safety and efficacy Sstudy of eltrombopag in subjects with AML clinicaltrials.gov\/ct2\/show\/NCT01890746"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0159|cit159","unstructured":"NCT01000051 Eltrombopag for post transplant thrombocytopenia clinicaltrials.gov\/ct2\/show\/NCT01000051"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1182\/blood.V126.23.738.738","article-title":"Eltrombopag for post-transplant thrombocytopenia: results of phase II randomized double blind placebo controlled trial","volume":"126","author":"Popat","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0161|cit161","unstructured":"NCT00299182 Study of AMG 531 to evaluate the safety & efficacy in patients with non-Hodgkin's lymphoma clinicaltrials.gov\/ct2\/show\/NCT00299182"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"Abstract 1544","DOI":"10.1182\/blood.V116.21.1544.1544","article-title":"Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): results of a phase I\/II study","volume":"116","author":"Vadhan-Raj","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010982.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0049-3848(83)90326-2","article-title":"DDAVP: does the drug have a direct effect on the vessel wall?","volume":"31","author":"Barnhart","year":"1983","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2003.04468.x","article-title":"Guidelines for the use of platelet transfusions","volume":"122","author":"British Committee for Standards in Haematology (BCSH)","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.04815.x","article-title":"Transfusion guidelines for neonates and older children","volume":"124","author":"British Committee for Standards in Haematology (BCSH)","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.2009.07840.x","article-title":"Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill","volume":"147","author":"Benson","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12026-009-8106-9","article-title":"The platelet as an immune cell - CD40 ligand and transfusion immune modulation","volume":"45","author":"Blumberg","year":"2009","journal-title":"Immunology Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0168|cit168","first-page":"372","article-title":"Platelet concentrates. Cross-sectional guidelines for therapy with blood components and plasma derivatives","volume":"36","author":"Board of the German Medical Association on the Recommendation of the Scientific Advisory Board","year":"2009","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0169|cit169","unstructured":"Bolton-Maggs PHB (editor) and H Cohen on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group The 2011 Annual SHOT Report www.shotuk.org\/shot-reports\/shot-annual-report-summary-2011\/"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","author":"Butler","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010982.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1537-2995.2007.01090.x","article-title":"Evaluation of platelet transfusion triggers in a tertiary-care hospital","volume":"47","author":"Cameron","year":"2007","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0173|cit173","unstructured":"Cancer Research UK Percentage change in European age-standardised three year average incidence rates, males, UK, 1991-2001 and 2008-2010 www.cancerresearchuk.org\/cancer-info\/cancerstats\/"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0174|cit174","unstructured":"CDC (Center for Disease Control and Prevention) United States Cancer Statistics nccd.cdc.gov\/uscs\/"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6601696","article-title":"Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001","volume":"90","author":"Coleman","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1537-2995.2004.03231.x","article-title":"Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers","volume":"44","author":"Cook","year":"2004","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"Serna","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0178|cit178","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010982.pub2-BIB0179|cit179","first-page":"20S","article-title":"Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures","volume":"52","author":"Desborough","year":"2012","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD010982.pub2-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012055","article-title":"Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review","author":"Desborough","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"28","key":"10.1002\/14651858.CD010982.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1002\/adma.201200607","article-title":"Platelet mimetic particles for targeting thrombi in flowing blood","volume":"24","author":"Doshi","year":"2012","journal-title":"Advanced Materials"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1423-0410.2012.01627.x","article-title":"Platelet transfusions in haematology patients: are we using them appropriately?","volume":"103","author":"Estcourt","year":"2012","journal-title":"Vox Sanguinis"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/trf.12058","article-title":"Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials","volume":"53","author":"Estcourt","year":"2013","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/trf.12441","article-title":"Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review","volume":"54","author":"Estcourt","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010983","article-title":"Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation","author":"Estcourt","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010981","article-title":"A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation","author":"Estcourt","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010984","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation","author":"Estcourt","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733.pub3","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders","author":"Estcourt","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1002\/14651858.CD010982.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD010982.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1537-2995.2007.01089.x","article-title":"Platelet utilisation and the transfusion trigger: a prospective analysis","volume":"72","author":"Greeno","year":"2007","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1046\/j.1537-2995.2003.00418.x","article-title":"Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies","volume":"43","author":"Heddle","year":"2003","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1537-2995.2008.01731.x","article-title":"Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review","volume":"48","author":"Heddle","year":"2008","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2008-09-178236","article-title":"A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia","volume":"113","author":"Heddle","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/9781444311761.ch6","article-title":"Investigation of acute transfusion reactions","volume-title":"Practical Transfusion Medicine","author":"Heddle","year":"2009"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0196|cit196","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0197|cit197","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0198|cit198","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in Statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0199|cit199","unstructured":"Knowles S (editor) Cohen H on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group The 2010 Annual SHOT Report www.shotuk.org\/shot-reports\/report-and-summary-2010-2\/"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1537-2995.2004.03153.x","article-title":"Measurement of bleeding severity: a critical review","volume":"44","author":"Koreth","year":"2004","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2010.02.005","article-title":"Biology and chemistry of thrombopoietic agents","volume":"47","author":"Kuter","year":"2010","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0202|cit202","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD010982.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD010982.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/j.1538-7836.2009.03633.x","article-title":"Pharmacokinetics and safety of fibrinogen concentrate","volume":"7","author":"Manco-Johnson","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0206|cit206","volume-title":"The National Blood Authority's Patient Blood Management Guideline: Module 3 - Medical","author":"National Blood Authority (NBA)","year":"2012"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0207|cit207","unstructured":"National Institute for Health and Care Excellence (NICE) Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura TA221 www.nice.org.uk\/Guidance\/TA221"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0208|cit208","unstructured":"National Institute for Health and Care Excellence (NICE) Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura TA293 National Institute for Health and Care Excellence 2013"},{"issue":"1","key":"10.1002\/14651858.CD010982.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.V100.1.136","article-title":"Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia\/IIa and Iba under flow conditions: specific synergy of receptor-ligand interactions","volume":"100","author":"Nishiya","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/bc900325w","article-title":"Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation","volume":"20","author":"Okamura","year":"2009","journal-title":"Bioconjugate Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1538-7836.2008.03269.x","article-title":"Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute","volume":"7","author":"Okamura","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0212|cit212","unstructured":"Office of National Statistics (ONS) Cancer Statistics Registrations, England: 2012 www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancerregistrationstatisticsengland\/2014-06-19"},{"issue":"24","key":"10.1002\/14651858.CD010982.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2012.66","article-title":"The EBMT activity survey: 1990-2010","volume":"47","author":"Passweg","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","article-title":"Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission","volume":"94","author":"Patel","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD010982.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1111\/trf.12175","article-title":"Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review","volume":"53","author":"Pavenski","year":"2013","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD010982.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-3148.2010.01037.x","article-title":"Screening of platelet for bacterial contamination at the Welsh Blood Service","volume":"21","author":"Pearce","year":"2011","journal-title":"Transfusion Medicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0218|cit218","first-page":"17","article-title":"An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?","volume":"34","author":"Pendry","year":"2011","journal-title":"Blood and Transplant Matters"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1537-2995.1985.25686071434.x","article-title":"Diagnostic and pathogenetic considerations in transfusion-related acute lung injury","volume":"25","author":"Popovsky","year":"1985","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(09)70028-2","article-title":"Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England","volume":"10","author":"Rachet","year":"2009","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0221|cit221","unstructured":"The Nordic Cochrane Centre Review Manager (RevMan) 2012"},{"issue":"1","key":"10.1002\/14651858.CD010982.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/09537100903388359","article-title":"Effect of beta-blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia","volume":"21","author":"Rysler","year":"2010","journal-title":"Platelets"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V64.1.229.229","article-title":"DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium","volume":"64","author":"Sakariassen","year":"1984","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0225|cit225","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/j.1537-2995.2009.02273.x","article-title":"ABO-identical versus non-identical platelet transfusion: a systematic review","volume":"49","author":"Shehata","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD010982.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2002-03-0958","article-title":"Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors","volume":"101","author":"Silliman","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0228|cit228","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005011.pub4","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","author":"Simpson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","article-title":"Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients","volume":"105","author":"Slichter","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0230|cit230","doi-asserted-by":"crossref","unstructured":"Slichter SJ Evidence-based platelet transfusion guidelines Hematology (American Society of Hematology Education Program) 2007 172 8","DOI":"10.1182\/asheducation-2007.1.172"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of haemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010982.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bja\/aeq058","article-title":"Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery","volume":"104","author":"Solomon","year":"2010","journal-title":"British Journal of Anaesthesia"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tmrv.2009.11.002","article-title":"Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions","volume":"24","author":"Stanworth","year":"2010","journal-title":"Transfusion Medicine Reviews"},{"issue":"19","key":"10.1002\/14651858.CD010982.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0235|cit235","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010982.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0049-3848(12)70004-X","article-title":"The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding","volume":"128","author":"S\u00f8rensen","year":"2011","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0237|cit237","unstructured":"Taylor C (Ed) Cohen H Mold D Jones H on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group The 2009 Annual SHOT Report www.shotuk.org\/shot-reports\/report-and-summary-2009\/"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0239|cit239","article-title":"Chapter 18: platelet transfusion, alloimmunization and management of platelet refractoriness","volume-title":"Canadian Blood Services","author":"Tinmouth","year":"2007"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","author":"The Trial to Reduce Alloimmunization to Platelets Study Group","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010982.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.transci.2009.07.005","article-title":"Platelet utilization in the developing world: strategies to optimize platelet transfusion practices","volume":"41","author":"Verma","year":"2009","journal-title":"Transfusion and Apheresis Science"},{"issue":"9850","key":"10.1002\/14651858.CD010982.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010982.pub2-BIB0243|cit243","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization (WHO)","year":"1979"},{"issue":"7","key":"10.1002\/14651858.CD010982.pub2-BIB0244|cit244","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008235.pub2","article-title":"TPO receptor agonist for chronic idiopathic thrombocytopenic purpura","author":"Zeng","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010982.pub2-BIB0245|cit245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004269.pub3","article-title":"Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation","author":"Estcourt","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010982.pub2-BIB0246|cit246","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010982","article-title":"Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation","author":"Estcourt","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010982.pub2-BIB0247|cit247","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004269.pub2","article-title":"Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation","author":"Stanworth","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010982.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:05:26Z","timestamp":1718852726000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010982.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":247,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010982.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}